News and Announcements
Actinogen Medical Appoints Dr Geoff Brooke as Chairman
- Published March 01, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Actinogen Medical is pleased to announce that is has appointed healthcare industry and venture capital veteran, Dr Geoff Brooke, as Chairman, effective 1st March.
KEY TAKEAWAYS:
- Appointed of healthcare industry and venture capital veteran, Dr Geoff Brooke, as new Chairman.
- Adds significant life sciences and financial expertise to the Actinogen Board, with Dr Brooke having 30 years’ international experience as the founder, lead investor and Chairman/Director of numerous healthcare companies.
- Dr Brooke was Managing Director and Founder of leading life sciences venture capital firm, GBS Ventures is a Non-Executive Director of ASX-listed company, Acrux Limited (ASX: ACR).
- Dr Brooke’s experience will be invaluable as Actinogen begins patient recruitment in their XanADu Phase II Alzheimer’s trial in early Q2 2017 and progresses through to study completion and data read-out in early 2019.
Dr Brooke was also President and Founder of US-based seed healthcare venture capital firm, Medvest Inc, with investors including the venture capital arm of leading global multinational medical devices, pharmaceutical and consumer packaged goods manufacturer, Johnson & Johnson. Medvest was focused on founding companies based upon health care-related technology, including pharmaceuticals, biotechnology, therapeutic devices, medical services and information systems.
Dr Brooke now acts a private investor in, and independent director for, a number of small to medium-sized Australian and US private and public companies, including Non-Executive Director for ASX-listed company, Acrux Limited (ASX:ACR).
He holds a Bachelor of Medicine and a Bachelor of Surgery from Melbourne University and a Masters of Business Administration from IMEDE Switzerland (now IMD).
“We are thrilled to have someone of Geoff’s calibre joining Actinogen as Chairman. Geoff brings a wealth of expertise across the Australian and US listed healthcare space and in-depth knowledge of all aspects of financing healthcare and life sciences companies,” said Dr Bill Ketelbey, CEO of Actinogen Medical.
“His knowledge will be invaluable as we progress through to study completion and data read-out of our XanADu Phase II clinical trial – the largest global Alzheimer’s dementia study conducted by an Australian biotech company – which is on target to treat first patients with Xanamem™ in early Q2 2017.”
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
